ASND250516P85000
- 0.00
- 0.000.00%
Ascendis Pharma A/S Newsroom
Ascendis Pharma Is Maintained at Outperform by RBC Capital
Ascendis Pharma Is Maintained at Outperform by Wedbush
Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group
Ascendis Pharma Analyst Ratings
RBC Raises Price Target on Ascendis Pharma to $210 From $205, Keeps Outperform, Speculative Risk
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $212
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $194
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $192
Ascendis Pharma Analyst Ratings
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180
Ascendis Pharma (ASND) Receives a Buy From Evercore ISI
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $192
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180
UBS Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $196
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200
Ascendis Pharma Price Target Raised to $200.00/Share From $168.00 by JP Morgan
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Ascendis Pharma Analyst Ratings